TRIM33 and cancer: Out of 72 patients with malignancy, 34 were positive for anti-TIF-1-γ (38.2% out of all anti-TIF1-γ-positive patients), 3 were anti-NXP-2-positive (7.14% out of all 42 patients with anti-NXP-2) and 4 were positive for anti-SAE (30.77% out of 14 anti-SAE-positive patients).